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synthesis [1–3]. The diphosphate derivative inhibits
ribonucleotide reductase, thereby depleting the endogenous deoxyribonucleotide triphosphate pools.
The triphosphate derivative is incorporated into DNA
and subsequently interferes with DNA chain elongation. Gemcitabine is deaminated to the inactive
metabolite 29,29-difluorodeoxyuridine (dFdU) by cytidine deaminase. Gemcitabine is used clinically to
treat a variety of solid tumors, particularly pancreatic, bladder and non-small cell lung cancers.
Preclinical studies conducted in our laboratory
suggested that the combination of dFdC for 4 h
followed by a 24-h exposure to 5-fluoro-29-deoxyuridine (FdU) resulted in more than additive cytotoxicity and enhanced DNA damage in a human colon
cancer cell line [4]. Therefore, a Phase I trial of
weekly dFdC followed by a 24-h infusion of FdU
was designed. To permit determination of the plasma
levels of dFdC and dFdU in patient samples, a
reversed-phase HPLC assay was developed.

Experimental conditions

Magnusen Clinical Center, NIH (Bethesda, MD,
USA).
Standard solutions
Stock solutions of dFdC, dFdU and FdC at
concentrations of 10 mM (2.63 mg / ml), 7.57 mM (2
mg / ml) and 10 mM (2.44 mg / ml), respectively,
were prepared in water; aliquots were stored at
230 8C. Calibration standards were prepared by
appropriate dilutions of the dFdC stock solutions
with water to generate 103 calibration standards at
concentrations ranging between 5 and 1500 mM;
aliquots were stored at 230 8C; dilutions of the
dFdU stock solutions with water generated 103
calibration standards ranging from 5 to 2270 mM.
Plasma calibration standards were made by adding
50 ml of a 103 calibration standard solution to 0.5
ml of plasma to give final concentrations upon
reconstitution of the extracted plasma sample that
ranged between 0.5 and 150 mM for dFdC or 0.5 and
227 mM for dFdU. Fifty microliters of 250 mM FdC
or 20 ml of 1 mM FdC was added to 0.5 ml plasma
to give a final concentration of 25 or 40 mM (see
Section 3.1).

Chemicals
Sample preparation
The commercial formulation of gemcitabine hydrochloride (each vial contains 200 mg of gemcitabine as the free base, 262.9 g / mol) was purchased from Eli Lilly and Company (Indianapolis,
IN, USA). dFdU was generously provided by Lilly
Research Laboratories though a material transfer
agreement with the National Cancer Institute (NCI).
FdC (HPLC internal standard), was purchased from
Sigma (St Louis, MO, USA). Tetrahydrouridine
(THU), an inhibitor of cytidine deaminase, was
provided by the Drug Synthesis and Chemistry
Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, NCI,
National Institutes of Health (NIH), Bethesda, MD,
USA [5]. Glacial acetic acid (analytic reagent (AR)
grade) and sodium acetate (AR grade) were from
Mallinckrodt (Paris, KY, USA). HPLC grade water,
methanol and acetonitrile were from Fisher (Fair
Lawn, NJ, USA). All other chemicals were AR
grade. Pooled donor plasma was obtained from the
Department of Transfusion Medicine, Warren G.

Standard curves were prepared in pooled plasma
which was placed on ice immediately upon thawing.
Aliquots of 0.5-ml test plasma were placed in 12375
mm glass tubes on ice; calibration standards and 20
ml of 1 mM internal standard were added. Glacial
acetic acid (50 ml) was added to decrease hydrogen
bonding between the nucleosides and proteins. After
the addition of 1 ml of acetonitrile, the samples were
vortex-mixed. Following centrifugation at 800 g for
15 min at 4 8C, the supernatant was removed. To
improve the recovery (see Section 3.2), 1 ml of
acetonitrile was added to the precipitate, the sample
was vortex-mixed followed by repeat centrifugation.
The supernatants were combined, and the sample
was evaporated to dryness using filtered compressed
air in a 42 8C water bath in a Zymark TurboVap 
(Hopkinton, MA, USA) and stored at 230 8C. On
the day of analysis, the residue was re-suspended in
0.5 ml HPLC water, incubated for 5 min in a 37 8C
water bath, and then clarified by centrifugation at
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12 000 g for 10 min at 20 8C. The resultant supernatant was filtered though a 1-ml syringe fitted with a
GHP 13-mm Acrodisc, 2-mm pore size, with minispike outlet (Pall Gelman Laboratory, Ann Arbor,
MI, USA). An aliquot of each sample was placed in
250-ml low volume glass inserts placed in 4-ml glass
vials (Waters, Milford, MA, USA) and loaded into a
48-position carousel tray. The injection volume was
190 ml. The residuals of the reconstituted samples
were stored at 230 8C in the event that repeat
injection was needed. Because the calibration standards were prepared in pre-chilled plasma on ice, the
inclusion of THU (final concentration 1 mM) during
their preparation did not affect either the recovery or
peak heights of the analytes or internal standard.
Blood samples from patients receiving 1000 mg /
m 2 of dFdC were obtained using 10-ml heparinized
tubes containing 10 nmol THU. The blood collection
tubes were immediately placed on ice until centrifugation at 1000 g for 10 min at 4 8C. Aliquots of
plasma were stored at 270 8C until analysis. Twenty
microliters of 1 mM FdC were added to 0.5-ml
aliquots of plasma, and the samples were then
prepared as described above.
High-performance liquid chromatography with
photodiode array detection
The Waters chromatographic system (Milford,
MA, USA) was used consisting of a 600E Multisolvent Delivery System, a 717 plus Autosampler set
at 4 8C, a 996 Photodiode Array Detector and an
in-line vacuum degasser. A Columbus姠 C 18 column
˚ pore size, 15034.6 mm)
(5-mm particle size, 110 A
was employed for the separations (Phenomenex,
Torrance, CA, USA). The pre-column was a Waters
C 18 Nova-Pak Sentry guard column (4-mm particle
size). A Micron Millennia computer (Nampa, ID,
USA) was used to acquire data and perform the
initial data analysis using Millenium 32 software
version 3.2 (Waters).
HPLC solvent A was 50 mM sodium acetate (pH
5.0) with 2% (v / v) methanol; solvent B was the
same buffer with 10% (v / v) methanol. Total flowrate was 1.5 ml / min and the column was at ambient
temperature. The following program was run: 100%
A for 17 min, a linear gradient of 100% A to 100%
B over 14 min, 100% B for 2 min, and immediate

return to 100% A and re-equilibration for 6 min.
FdC, dFdC and dFdU were monitored at wavelengths of 282, 269 and 258 nm, respectively.
Calculations
The ratios of the peak heights of dFdC or dFdU to
FdC were calculated, which were then plotted versus
the nominal total amount of dFdC or dFdU in the
sample. The data were fitted using least squares
linear regression with a weighting factor of 1 /y, not
including the origin, using SigmaPlot 2001 (SPSS,
Chicago, IL, USA). Analyte concentrations were
determined using the calibration lines thus generated.
Recovery
Plasma samples were prepared in triplicate containing six concentrations ranging from 0.5 to 100
mM of dFdC and dFdU; each sample contained a
fixed concentration of FdC (25 mM). Non-treated
standards were samples in which the same concentration of the internal standard, dFdC or dFdU
were prepared in water and not subjected to the
precipitation procedure. The percent absolute recovery was defined as the (peak height of the
precipitated plasma standard4peak height of the
non-treated standard)3100%.
Validation
Concentrations of dFdC and dFdU were determined by three calibration curves run over a 3-week
period to compare the observed with the theoretical
concentration. To determine within-run variation,
triplicate samples at six different concentrations of
dFdC and dFdU were prepared in human plasma,
and the samples were injected on the same day.
Between-run variation was determined by injecting
triplicate samples prepared at three different concentrations on three separate occasions.
Stability of samples
The stability of the stock solutions of dFdC, dFdU
and FdC was tested by preparing three concentrations of the compounds in water, and analyzing an
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aliquot immediately and after storage at room temperature and at 230 8C.
Analysis of patient plasma samples
Patients were participating in an Institutional
Review Board-approved Phase I clinical trial involving dFdC given as either a 1- or 2-h infusion
followed by a 24-h infusion of FdU weekly for 3 of
4 weeks. All patients gave written, informed consent.
A baseline plasma sample was obtained pre-therapy.
To provide an estimate of steady-state gemcitabine
plasma concentrations, samples were obtained at 30,
40 and 50 min during the 1-h infusion, and at 90 and
105 min during the 2-h infusion.

Results
High-performance liquid chromatography
FdC, dFdC and dFdU were resolved from endogenous compounds with resulting retention times of
13.660.5, 18.161.1 and 29.060.6 min, respectively.
dFdC and dFdU were monitored at their optimal UV
wavelengths, 269 and 258 nm, respectively, under
the experimental conditions as determined by spectral analysis using the photodiode array detector.
Because an endogenous peak (that was not present
when FdC stock solution was directly injected)
eluted shortly after FdC, we compensated by increasing the amount of the internal standard from 25 to 40
mM, and monitoring the peak height at 282 nm.
These measures provided a greater peak height for
FdC and allowed baseline resolution between FdC
and the adjacent endogenous peak (Fig. 2). THU is
not detectable under the conditions used.
Recovery
Absolute recovery of FdC, dFdC and dFdU from
plasma was compared to non-extracted samples
prepared in water under identical concentrations. In
preliminary studies, it was determined that the
recovery was about 10% greater when the samples
were filtered though a GHP 0.2-mm syringe filter
compared to the use of a PVDF filter. Application of

a second acetonitrile precipitation improved the
absolute recoveries by about 17% over that achieved
with a single precipitation with 1 ml acetonitrile;
recovery with two sequential 1-ml precipitations was
also greater than a single precipitation with 2 ml
acetonitrile (data not shown). With the sample preparation described herein, the overall recovery of all
three analytes from 0.5 ml plasma was $70% for
dFdC, $68% for FdC, and $82% for dFdU (Table
1).

Accuracy and precision
Data from three calibration curves prepared with
six standard concentrations of dFdC and dFdU with a
fixed FdC concentration that were examined over a
3-week period are shown in Table 2. The percent
coefficients of variation (% CV) for dFdC were
below 3% at concentrations $5 mM, and were below
10.2% for 1 and 0.5 mM. There was greater variability with dFdU: the %CV was 22.2% with 0.5
mM, but was below 7% for higher concentrations
with the exception of 5 mM (%CV 11.5%). The
average r 2 values for the three calibration curves
were above 0.998 for both dFdC and dFdU.
Within-run variation was assessed using six concentrations of dFdC and dFdU with fixed concentrations of FdC (25 mM) and THU (1 mM) prepared
in triplicate. The results of within-run variation were
determined by comparing the peak heights for dFdC,
dFdU and FdC for these nine separate samples
injected into the HPLC system on the same day. The
coefficients of variation ranged from 1.1 to 6.0% for
dFdC, and were ,4.3% for dFdU and FdC (Table
3). Assessment of between-run variability was carried out subsequently using concentrations of dFdU
and dFdC that would encompass the expected plasma
concentrations taken from patients during the 1- to
2-h dFdC infusion. The coefficients of variation were
#5.1% for three compounds (Table 4).

Linearity
The assay was linear between 0.5 and 150 mM
(0.13–39.4 mg / ml) for dFdC and 1 to 227 mM
(0.26–60.0 mg / ml) for dFdU.
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Fig. 2. Chromatography and UV detection of dFdC and dFdU in the plasma of a patient 40 min after the start of a 1-h infusion of 1000
mg / m 2 of dFdC. Identified peaks include the internal standard, dFdC and dFdU. The calculated plasma concentrations of dFdC and dFdU
were 23.7 and 59.2 mM, respectively.

Table 1
Absolute recovery of internal and calibration standards
Analyte
dFdC

dFdU

FdC

Mean
SD
%CV
Mean
SD
%CV
Mean
SD
%CV

0.5 mM

1 mM

5 mM

10 mM

50 mM

150 mM

75.8
1.2
1.6
95.2
2.6
2.8
68.3
1.8
2.7

78.8
0.9
1.1
86.4
1.0
1.2
76.2
1.5
2.0

80.2
1.2
1.5
87.4
1.7
2.0
67.9
1.5
2.2

86.3
3.5
4.1
81.8
3.5
4.3
83.4
3.5
4.2

70.0
2.6
3.8
87.5
0.8
0.9
68.0
2.1
3.1

78.5
4.7
6.0
101.4
2.2
2.2
75.8
0.9
1.2

Triplicate samples of internal standard (fixed concentration of 25 mM) and calibration standards were prepared in both plasma and water.
The plasma was subjected to the sample preparation described in Section 2, whereas aliquots of the standards prepared in water were
directly injected into the HPLC without further processing.
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Table 2
Gemcitabine (dFdC) and 29,29-difluorodeoxyuridine (dFdU) calibration standards in human plasma
Concentration
(mM)

Measured dFdC (mM)
(mean6SD)

150
50
10
5
1
0.5

152.163.0
48.761.2
9.460.3
4.860.10
1.060.1
0.5360.05

Calibration curve parameters
2

r
X-coefficient
Y-intercept

dFdC
%CV

Measured dFdU (mM)
(mean6SD)

2.0
2.5
2.7
2.0
10.2
8.8

dFdU
%CV

152.463.4
48.261.5
9.860.7
4.760.5
1.160.0
0.5260.11

dFdC

dFdU

0.998960.0009
0.07560.005
20.003860.0095

0.998560.0014
0.06760.016
0.026260.0360

2.2
3.1
6.7
11.5
1.6
22.2

The data are from three calibration curves in human plasma done over a 3-week period. The internal standard concentration was 40 mM.
Table 3
Within-run precision for gemcitabine (dFdC) and 29,29-difluorodeoxyuridine (dFdU) in human plasma
25 mM FdC

Concentration
(mM)

dFdC

dFdU

Peak height

SD

%CV

Peak height

SD

%CV

Peak height

SD

%CV

05
1
5
10
50
150

1917
4614
22 625
53 242
223 332
896 568

73
274
334
2186
3488
9901

38
59
15
41
16
11

2232
5413
21 226
40 011
229 301
600 932

62
119
422
1732
2037
7148

28
22
20
43
09
12

76 717
79 946
76 761
77 222
73 603
68 415

627
1571
1954
3214
5146
831

08
20
26
42
70
12

The data are from samples prepared in triplicate and injected during the same HPLC run.

month, and at both 4 8C and room temperature for at
least 1 week (data not shown).

Stability
It has been reported that both gemcitabine and
dFdU are stable for at least 21 months at 270 8C in
THU-treated human plasma, and that both analytes
were unaffected by three freeze–thaw cycles [8].
Therefore, we did not repeat this analysis. In the
current study, stock solutions of 1 mM FdC, 1 mM,
100 and 10 mM dFdC, and 7.57 mM, 378.5 and
37.85 mM dFdU were stable at 230 8C for at least 1

Testing of patient plasma samples
Plasma dFdC and dFdU concentrations were determined as part of a Phase I trial of weekly dFdC
followed by infusional FdU. The plasma concentrations for six patients each receiving 1000 mg / m 2
dFdC as either a 1- or 2-h infusion are shown in Fig.

Table 4
Between-run precision for gemcitabine (dFdC) and 29,29-difluorodeoxyuridine (dFdU) in human plasma
40 mM FdC

Concentration (mM)

dFdC

dFdU

dFdC

dFdU

Peak height

SD

%CV

Peak height

SD

%CV

Peak height

SD

%CV

5
25
100

15
95
227

25 449
125 054
524 059

389
962
10 345

15
08
20

74 850
428 440
1 009 497

1755
21 737
39 371

24
51
39

107 342
108 677
112 268

3007
3053
1977

24
28
18

The data are from samples prepared in human plasma in triplicate and injected on three different days.
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Fig. 3. Plasma concentrations of dFdC and dFdU in patients
receiving 1000 mg / m 2 gemcitabine. The data, shown as the
mean6SD, are from six patients who each received either a 1-h or
2-h infusion.

3. There were no interfering endogenous peaks in the
pre-therapy samples under the conditions used. In all
patients, dFdC and dFdU were detected at the
planned sampling times. The dFdC levels were
similar at 30, 40 and 50 min in patients receiving a
1-h infusion, and at 90 and 105 min in those
receiving a 2-h infusion, suggesting the drug was at
or near steady-state. The average plasma levels for
all time points for the 1-h infusion, 30.7 mM, was
about twofold higher than that observed with the 2-h
infusion, 15.2 mM. In contrast, the dFdU levels
appeared to be increasing throughout the infusion,
and were on average 3.2- and 7.6-fold higher than
the corresponding dFdC levels at the 50- and 105min sampling times after the start of a 1- and 2-h
infusion, respectively. This observation is consistent
with a longer half-life for dFdU, which is cleared by
renal excretion, as opposed to the predominantly
metabolic clearance of dFdC.

acetate, or acetonitrile. We found that liquid–liquid
extraction with two sequential acetonitrile applications yielded the best recovery.
Several studies have been published that describe
analysis of dFdC and dFdU in plasma samples
obtained from cancer patients receiving gemcitabine
[6–10]. However, only a few employed an internal
standard and provided sufficient information to ensure method reproducibility [6,9]. The first validated
assay reported from researchers at Lilly Research
Laboratories used normal-phase HPLC with an
Alltech姠 amino column [6]. The procedure required
sequential liquid–liquid extraction using both isopropanol and ethyl acetate followed by concentration
to dryness; the reconstituted residue was then filtered
though an ultra-free MC filter to remove insoluble
material. The mobile phase represented an aqueous
mixture containing five different solvents.
An additional published method used acetonitrile
precipitation for sample preparation, and an isocratic
mobile phase of 15 mM ammonium acetate, pH 5.0,
and acetonitrile (97.5:2.5, v / v) for 47 min followed
by a linear increase to 15 mM ammonium acetate,
pH 5.0, and acetonitrile (95:5, v / v) over 5 min [9].
The latter solvent was run isocratically for 10 min
followed by a linear return over 5 min to initial
conditions. The column was allowed to equilibrate
for 10 min prior to the next injection, for an overall
cycle time of 77 min to resolve dFdC, dFdU and the
internal standard, 29,29-difluorodeoxythymidine.
The current method employs reversed-phase
HPLC that offers a shorter cycling time (39 min),
partly due to the selection of the internal standard
FdC, which elutes sooner than dFdC and has similar
recovery. This method has proven useful in the
analysis of samples from patients receiving dFdC
given as a 1- or 2-h infusion weekly for 3 of 4
weeks. By using a smaller volume of plasma (0.1–
0.2 ml), the methodology described herein can also
be employed in the analysis of samples obtained
during a 30-min infusion of dFdC.

Discussion
In the process of developing the current method,
we evaluated several methods for sample preparation, including solid-phase extraction using different
types of cartridges (phenylboronate, C 18 ), and liquid–liquid extraction using either methanol, ethyl
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